Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Maxim's most advanced therapeutic candidate, Ceplene (histamine dihydrochloride), is designed to prevent or inhibit oxidative stress, thereby reversing immune suppression and protecting critical immune cells and to protect or reverse tissue damage caused by the free radicals. Ceplene has demonstrated efficacy and safety in 17 clinical trials in 20 countries, including four Phase III studies that are completed or under way. More than 2,000 patients have participated in clinical trials for advanced metastatic melanoma, acute myelogenous leukaemia, renal cell carcinoma and hepatitis C.